NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell and a central player in energy metabolism. It has become a major focus of aging and metabolic research because cellular NAD+ levels decline with age. This primer summarizes the research context for educational reference only.
What is NAD+?
NAD+ is an essential coenzyme that shuttles electrons in the reactions that produce cellular energy. It also serves as a substrate for enzymes involved in DNA repair and cellular signaling. As a research compound it is supplied as a lyophilized powder.
Research focus areas
- Cellular energy: central to mitochondrial electron-transport and ATP-production research.
- DNA repair and sirtuins: a required substrate for enzymes studied in longevity research.
- Aging models: investigated because tissue NAD+ declines with age.
Handling and quality
Reconstitute lyophilized NAD+ with bacteriostatic water for research handling, and store protected from light. Confirm purity and identity through a batch-specific Certificate of Analysis before use. Browse the full research peptide catalog.
For laboratory and research use only. Not for human or animal consumption. This article summarizes publicly available research and is not medical advice.
The short version
Almost every analytical habit built up around a peptide catalog misfires on this compound, because it is not a peptide. NAD+ is a small-molecule dinucleotide coenzyme with a single fixed structure, no sequence, no residues, and no solid-phase synthesis history. That changes what a certificate should contain, which instruments settle identity, what the credible impurities are, and how a purity percentage should be read. It also introduces two problems a peptide never poses: the material exists as a redox pair whose two members have different spectra and opposite chemical sensitivities, and it is genuinely labile in solution rather than merely inconvenient. The sections below work through the small-molecule identity toolkit, the oxidized and reduced species and how to keep them straight, why solution handling dominates practical work, what a nucleotide purity figure is measuring, and where the settled biochemistry ends and a much weaker literature begins.
Why the peptide toolkit misses on this molecule
A peptide is defined by an ordered sequence, and everything in a peptide certificate follows from that. Identity means confirming the sequence, usually by comparing an observed mass against the mass calculated from the sequence, occasionally by fragmentation. Purity means reversed-phase separation with detection near 214 nanometers, where the peptide bond itself absorbs, so that every species carrying a backbone responds roughly in proportion to its size. The credible impurities are the ones synthesis produces: deletion sequences, truncations, incompletely deprotected material, residual scavengers and salts. There is no authentic reference material for most research peptides, so the whole structure of the document is a comparison against a calculation rather than against a physical standard.
Nothing in that paragraph survives the move to a dinucleotide. There is no sequence to confirm, so a mass measurement is not confirming an ordering of subunits; it is confirming an elemental composition. There is no peptide bond, so 214 nanometers is not the right detection window, and the chromophores that do matter are the adenine ring and, in the reduced form, the dihydropyridine ring. There are no coupling failures, so the impurity classes that dominate peptide work simply do not exist here. And, unlike almost everything else in a research catalog, a genuine reference material for this compound is obtainable, because it has been a commercial biochemical reagent for the better part of a century and appears in pharmacopeial-style monographs.
That last point reorganizes the whole documentation question. When an authentic standard exists, identity stops being an argument from calculation and becomes a comparison: does the sample match the standard on retention, on spectrum, on mass, on nuclear magnetic resonance. A supplier who cannot produce that comparison is choosing not to, rather than being unable to.
The methods that do the work are the ordinary small-molecule set. Proton nuclear magnetic resonance resolves the aromatic protons of the nicotinamide and adenine rings and the anomeric protons of the two riboses, which together establish that the expected fragments are present and connected. Phosphorus nuclear magnetic resonance shows the two inequivalent phosphorus environments of the pyrophosphate bridge, which is direct evidence of the linkage that joins the halves. High-resolution mass measurement fixes the elemental composition rather than a sequence. Ultraviolet spectroscopy gives a characteristic profile dominated by the adenine absorbance near 260 nanometers. Optical rotation reports on the two ribose stereocenters. Each of these settles a different question, and none of them is a sequence confirmation, because there is no sequence.
The same certificate question, answered two different ways
| Question | Peptide workflow | Dinucleotide workflow |
|---|---|---|
| What establishes identity | Observed mass compared against mass calculated from the stated sequence | Elemental composition by exact mass, plus nuclear magnetic resonance and comparison against a reference standard |
| Primary separation | Reversed-phase gradient, aqueous acetonitrile with acid modifier | Ion-pairing reversed-phase or hydrophilic interaction chromatography for a polar anion |
| Detection window | Near 214 nanometers, the peptide bond | Near 260 nanometers for adenine; 340 nanometers reports only reduced material |
| Reference material | Rarely available; the theoretical mass is the reference | Authentic standards exist and can be run alongside the lot |
| Expected impurities | Deletion and truncation sequences, protecting groups, scavengers | Hydrolysis fragments, the free base, the reduced form, the phosphorylated relative |
| Content correction | Net peptide content against salt and water | Water by Karl Fischer or loss on drying; salt form stated explicitly |
| Functional check | Rarely applicable on a certificate | Enzymatic activity in a dehydrogenase system |
The practical consequence is that a certificate written on a peptide template and applied to this material will look complete while answering the wrong questions. A purity figure at 214 nanometers, a theoretical mass with no stated salt form, and no water figure is a document that has been reformatted rather than reconsidered. The useful test when reviewing one is to ask which of the seven rows above the document actually addresses. Two or three is common. Five or more is a supplier who understands what they are selling.
The redox pair, and what a bare NAD figure omits
The oxidized and reduced forms are not two products. They are two states of one molecule, interconverted by a hydride at a single ring position, and a sample of either one contains some of the other. That single fact is why a number reported as a NAD concentration, with no further qualification, cannot be interpreted. It could mean the oxidized species, the reduced species, the arithmetic sum of both, or the ratio between them, and those four figures move independently.
The spectroscopic distinction is what makes the pair tractable at all. Both forms carry the adenine ring, so both absorb strongly near 260 nanometers, and that band is essentially indifferent to what is happening at the nicotinamide end of the molecule. Reduction, however, converts the aromatic pyridinium ring into a dihydropyridine, and that new chromophore absorbs at 340 nanometers, where the oxidized form has effectively no absorbance at all. So the reduced form absorbs where the oxidized form does not, and a single wavelength reading at 340 nanometers is a selective measurement of reduced material in a mixture of the two. The entire tradition of following dehydrogenase reactions spectrophotometrically rests on that one asymmetry.
What the spectrum cannot do is equally important. It does not distinguish the unphosphorylated coenzyme from its 2-phosphate relative, because the extra phosphate sits on the adenosine ribose, far from either chromophore, and contributes nothing to the ultraviolet profile. A laboratory that reports a 340 nanometer measurement as a reduced-coenzyme concentration in a biological extract, without a separation step, is reporting the sum of two different reduced pools that the cell holds at very different oxidation states and uses for different chemistry.
The harder problem is that the ratio between oxidized and reduced forms is altered by sample handling before any instrument sees the sample. The two forms interconvert enzymatically in a living system on a timescale far shorter than most extraction procedures, so anything that slows quenching, allows the sample to warm, or permits continued dehydrogenase activity shifts the balance. The two forms are also destroyed by opposite conditions, which means the extraction chemistry itself is selective: an acidic extraction preserves the oxidized form and destroys the reduced one, and an alkaline extraction does the reverse. That is a genuinely useful tool when it is deliberate, because it is the classical way to measure the two pools separately. It is a silent source of error when it is not, because a laboratory that uses one extraction and reports a total is reporting a number that its own chemistry has truncated.
Species in play, and what moves each reading
| Species | How it is distinguished | What perturbs the reading |
|---|---|---|
| Oxidized form (NAD+) | Adenine band near 260 nanometers with no absorbance at 340; retention on ion-pairing or polar-phase chromatography | Alkaline conditions degrade it; alkaline extraction removes it selectively |
| Reduced form (NADH) | Absorbance at 340 nanometers, where the oxidized form has none | Acidic conditions degrade it; slow quenching lets enzymes reoxidize it |
| Phosphorylated relatives (NADP+ and NADPH) | Not separable by spectrum; requires chromatography or mass measurement | Reported as part of the pool whenever a spectroscopic method is used without separation |
| Total pool | Sum of oxidized and reduced, only meaningful if both were preserved | Any single-condition extraction destroys one of the two contributors |
| Redox ratio | Requires both forms measured on the same sample by compatible methods | Warming, delay before quenching, and continued enzyme activity all shift it |
| Free base (nicotinamide) | Chromatographic separation; weak and unhelpful spectral contrast | Accumulates as the molecule hydrolyzes, so it grows with sample age |
The reporting discipline that follows is simple and rarely observed. Any figure should name the species, the method, the extraction chemistry and whether a separation step preceded detection. A certificate or a paper that says NAD and gives a number has not stated which of the six rows above it is talking about. When two sources disagree about a concentration in the same tissue or the same lot, the first thing to check is not the biology but whether the two were measuring the same species by compatible chemistry. A surprising fraction of apparent disagreements close on that question alone.
Solution instability is the dominant practical problem
Most reagents in a research catalog are stable enough in solution that handling is a matter of good habit. This one is not. It is hydrolytically unstable, its reactive ring position is open to attack by common buffer components, and the two redox forms prefer opposite pH ranges, so there is no single condition under which both are comfortable. Work that ignores this produces results whose variability looks biological and is in fact chemical.
The pH problem is the central one. The oxidized form carries a positively charged pyridinium ring whose carbon opposite the ring nitrogen is electron-poor and therefore open to nucleophilic attack. Hydroxide is the obvious nucleophile, so degradation accelerates as pH rises above neutrality. The reduced form has that position already occupied and is no longer a pyridinium, but the dihydro ring is susceptible to acid-catalyzed chemistry instead, so it degrades in mildly acidic conditions and is comparatively comfortable in alkali. Neutral to slightly acidic for the oxidized form, neutral to slightly alkaline for the reduced one, and no shared optimum. A laboratory that keeps a single buffer on the shelf for both is accepting an ongoing loss in one of them.
The nucleophile problem is broader than pH. The same reactive ring position adds cyanide, bisulfite and a range of carbonyl compounds to give adducts, so buffer composition is not a neutral background here the way it is for an inert reagent. A component chosen for an unrelated reason can quietly consume the coenzyme, and the resulting loss of activity looks like a bad lot rather than a buffer incompatibility. Reviewing what else is in the solution should be an early step when activity is unexpectedly low, not a late one.
Two operational habits follow. Prepare solutions fresh and treat them as working reagents with a short useful life rather than stock to be kept. Aliquot into single-use volumes so that a stock is never thawed twice, because freeze-thaw cycling degrades solutions measurably and the damage is cumulative and invisible.
There is one piece of luck worth exploiting. Alkaline degradation of the oxidized form yields products that are yellow and fluorescent, so a solution that was water-clear when prepared and now carries a visible yellow cast has reported its own condition before any measurement is made. That is a free quality check available to anyone with eyes, and the correct response is to discard rather than to compensate, because the degradation products are not a single well-defined species and cannot be subtracted out.
Conditions and what each does to the two forms
| Condition | Effect on the oxidized form | Effect on the reduced form |
|---|---|---|
| pH above neutral | Degrades, with the rate climbing steeply as pH rises | Comparatively stable; this is its preferred range |
| pH below neutral | Comparatively stable; this is its preferred range | Degrades readily in mildly acidic solution |
| Nucleophilic buffer components | Adds at the reactive ring position to give adducts | Ring position already occupied, so far less susceptible |
| Repeated freeze-thaw | Cumulative measurable loss; single-use aliquots avoid it | Cumulative measurable loss; single-use aliquots avoid it |
| Time in solution at room temperature | Hydrolysis proceeds; free base and fragments accumulate | Hydrolysis proceeds and reoxidation is also possible |
| Moisture uptake by the solid | Corrupts weighing and accelerates degradation of the remaining powder | Same, and the solid form is likewise hygroscopic |
| Visible yellowing of a solution | Alkaline degradation products, fluorescent; discard the solution | Not the diagnostic sign for this form; judge by absorbance instead |
The reason this section matters more than it appears to is that instability converts into apparent irreproducibility downstream. A solution prepared on Monday and used on Thursday is not the same reagent, and a comparison between two experimental arms that used solutions of different ages has a confound built into it that no statistical treatment will remove. Recording preparation date, buffer composition and pH alongside the lot number costs nothing and is the difference between diagnosing a drift and arguing about it.
Purity by HPLC when the analyte is a nucleotide
A purity percentage is an area ratio: the main peak divided by the total integrated area, expressed as a percentage. That arithmetic is identical whatever the analyte. What differs completely is which species show up in the total, how strongly each one responds, and whether the separation resolved them at all.
Start with the separation, because a purity figure computed from a chromatogram that did not separate anything is arithmetic performed on a mistake. This is a small, highly polar, anionic species. On the conventional reversed-phase gradient that a peptide laboratory runs by default, it is barely retained and comes off near the void volume together with structurally related nucleotides, which means related-substance impurities are integrated into the main peak and the reported purity is inflated. The methods that actually retain and resolve it are ion-pairing reversed-phase, in which an alkylamine or tetraalkylammonium additive gives the anion something to hold against, and hydrophilic interaction chromatography, which retains polar analytes on a polar stationary phase. A certificate that does not name the mode has not told you whether the number means anything.
Then the response question. Area percent is not mole percent, because different species have different molar absorptivity at whatever wavelength the detector is set to. At 260 nanometers the response is dominated by the adenine ring, so every fragment that retains adenine, including the ribosylated fragment left behind when the free base is lost, responds strongly and appears at close to its true proportion. The free base itself, which retains no adenine, absorbs far more weakly in that region, so its peak area understates how much of it is present. The same chromatogram read at 340 nanometers inverts the picture entirely: only reduced material has any absorbance there, so a trace that looks like a clean single peak at 260 can show an unmistakable reduced-form peak at 340 that the first wavelength buried under the main band.
That is the practical rule for this compound. An impurity invisible at one wavelength can be obvious at another, and the only way to see the whole picture is diode-array detection with the chromatogram extracted at more than one wavelength, or a mass detector. A single-wavelength purity figure is a partial view by construction, and the wavelength is the single most informative number on the document after the percentage itself.
Finally, the impurity list should be named rather than lumped. The credible degradants here are chemically predictable, and a certificate that reports total impurities without identifying the largest one is withholding the information that would let a reader judge whether the lot is fresh, poorly stored, or from a route that leaves a characteristic fragment behind.
Credible impurities and how each one presents
| Impurity | Where it comes from | How it presents on a chromatogram |
|---|---|---|
| Reduced form (NADH) | Manufacturing route or subsequent handling | Invisible at 340 nanometers only in its absence; obvious there, easily buried at 260 |
| Free nicotinamide | Cleavage of the bond between the base and its ribose | Separates well on a retaining method; area understates it at 260 nanometers |
| ADP-ribose | The other half left behind when the base is lost | Retains adenine, so responds strongly at 260 and is hard to miss on a resolving method |
| Phosphorylated relative (NADP+) | Carryover or a related-manufacture impurity | Spectrally identical; only chromatography or mass measurement separates it |
| Adenine-containing fragments (AMP, ADP) | Further hydrolysis of the pyrophosphate bridge | Strong at 260 nanometers; elution order depends entirely on the separation mode |
| Alkaline degradation products | Storage or preparation above neutral pH | Yellow and fluorescent, often a cluster of poorly resolved late or early peaks |
Reading a certificate for this material therefore means reading three things before the percentage: the separation mode, the detection wavelength or wavelengths, and the identity of the largest single impurity. A document giving a percentage alone is not comparable with any other document, because the same lot will produce visibly different numbers on a poorly retaining method at one wavelength and a resolving method at two. Comparing purity figures across suppliers without those three fields is comparing method choices rather than materials.
Where the settled biochemistry stops and the weak literature starts
Two bodies of writing use the same compound name, and they have very different evidential standing. Conflating them is the most common failure in secondary writing about this molecule, and the conflation is usually not deliberate: the first body of work is so solid that its credibility leaks into anything printed next to it.
The first body is the enzymology of the coenzyme in central metabolism, and it is textbook material in the strict sense. Hydride transfer at the nicotinamide ring, the stereospecificity of that transfer at a prochiral carbon, the stoichiometry of the dehydrogenase reactions, the role of the reduced form as the electron donor at the entry point of the respiratory chain, the distinction between the unphosphorylated pool held oxidized for catabolism and the phosphorylated pool held reduced for biosynthesis: none of this is contested anywhere. It was established across the middle of the twentieth century by methods that are still taught, and it has been confirmed thousands of times over by anyone who has ever run a dehydrogenase assay. The biosynthetic routes and the salvage enzymology are similarly well founded, with the compartment-specific distribution of the biosynthetic enzymes as a somewhat more recent and still solid addition.
The second body concerns what happens when the coenzyme or one of its precursors is added to a system, and it is a different animal entirely. Much of it is preclinical. Much of the preclinical work is in rodents, where baseline concentrations, salvage flux and consuming-enzyme expression are not human values, so effect sizes do not transfer across the species gap. The reported decline in tissue concentrations with age is repeated far more often than it is independently reproduced across methods, and because the compound is labile under exactly the conditions used to extract it, the reported magnitude varies substantially with how quickly a sample was frozen and how it was processed. Disagreements that look biological are sometimes analytical.
The intervention studies compound this in a specific way. Most of them use a precursor rather than the coenzyme itself, because the intact molecule is large and highly charged and does not readily cross an intact membrane. Most of them measure the concentration of the compound or its metabolites in an accessible compartment. That is a pharmacokinetic endpoint. It establishes that a supplied precursor changes a measurable metabolite concentration somewhere it can be sampled. It does not establish a functional consequence anywhere, and the tissues that motivated the interest are typically not the tissues sampled.
The honest summary is that reading a metabolite concentration change as a functional finding is unsupported, and reading a rodent effect size as a human one is unsupported, and a great deal of writing about this compound does both in the same paragraph.
Evidential standing by claim type
| Claim type | Standing | What it does not support |
|---|---|---|
| Hydride transfer chemistry and dehydrogenase stoichiometry | Textbook; settled for decades and confirmed by routine assay | Nothing here is contested, and nothing here is about supplementation |
| Salvage and de novo biosynthetic enzymology | Well established, with compartment-specific detail more recent | Does not imply that adding material changes flux through those routes |
| Consuming-enzyme families that cleave the molecule | Established chemistry; the pool is both recycled and consumed | Does not establish that consumption is limiting in any given system |
| Reported tissue decline with age | Reported repeatedly; reproduction across methods and species is uneven | Magnitudes should not be transferred across tissues, species or assays |
| Precursor supplementation raising measurable metabolites | Pharmacokinetic endpoints, generally small and short studies | Does not establish any functional consequence in any tissue |
| Downstream functional claims in humans | Not established by the pharmacokinetic literature that is usually cited for it | No claim of this kind is supported by anything on this page |
The useful reading habit is to ask, of any sentence about this compound, which of those six rows it belongs to, and then to check whether the citation attached to it belongs to the same row. A sentence from row five supported by a citation from row one is the characteristic move, and it is common enough that noticing it is most of the work. Nothing in this catalog is offered for use in humans or animals, and nothing in the literature described above changes that.
Label strings in circulation and what they actually name
Five or six distinct chemical entities circulate under an overlapping marketing story, and the story treats them as interchangeable stages of one thing. They are not interchangeable. They differ in formula, in mass, in charge, in salt form, in which enzymes act on them, and in which analytical method will even retain them. A certificate that names one of them is describing that one and nothing else, and a document that says only NAD is describing an ambiguity.
The two redox states are one molecule in two conditions, and they are usually supplied in different physical forms as well. The oxidized form is commonly offered either as the free acid or as a sodium salt, frequently hydrated, and those forms have different formula weights, which means the number to weigh against comes from the specific certificate rather than from any general figure. The reduced form is commonly supplied as a disodium salt. A certificate that omits the salt form and hydration state has omitted the information required to convert a weight into an amount of substance, and there is no way to recover it from the compound name.
The precursors are separate compounds, not diluted versions of the coenzyme. The mononucleotide is one half of the dinucleotide, the nicotinamide-ribose portion with its phosphate but without the adenosine half. The riboside is one step further back again, with no phosphate at all, and is commonly supplied as a chloride salt. The free base and the acid form of vitamin B3 enter the biosynthetic pathway by different routes with different enzymes. Each of these has its own molecular formula, its own retention behavior and its own ultraviolet profile, and none of them will be mistaken for the coenzyme by any competent analysis.
Which raises the practical question of how to tell what a certificate is actually describing. The compound name at the top is the weakest evidence on the document, because it is the field most easily copied from a template. The strong fields are the ones that cannot be faked without effort: a molecular formula and a formula weight consistent with the stated salt and hydration state, a chromatographic method appropriate to a polar anion, a mass value that matches the named entity rather than one of its neighbors, and a nuclear magnetic resonance spectrum whose reported features are consistent with the claimed structure. When those fields agree with each other and with the name, the name is supported. When the name is the only place the compound is identified, the document has asserted an identity rather than demonstrated one.
Overlapping label strings and how to check them
| Label string | What the compound is | What the certificate must state |
|---|---|---|
| NAD+ | The intact dinucleotide, oxidized, with the pyridinium ring | Free acid or sodium salt, hydration state, formula weight used, water content |
| NADH | The same molecule reduced at the ring; commonly a disodium salt | Salt form, and absorbance data establishing the reduced form is the major species |
| NMN | One half of the dinucleotide: base, ribose and phosphate, no adenosine | Distinct formula and mass; a separation method that resolves it from the dinucleotide |
| NR | Base and ribose with no phosphate; commonly supplied as a chloride salt | Counterion named, since the salt changes the formula weight substantially |
| Nicotinamide | The free base alone, a simple aromatic amide and a vitamin B3 form | Small-molecule identity data; it responds weakly at 260 nanometers |
| Nicotinic acid | The acid form of vitamin B3, entering biosynthesis by a separate route | Clear distinction from the amide, which the name alone does not provide |
The single most useful habit is to record, in the receiving log, the exact entity and salt form rather than the marketing string, and to carry that through into every downstream record. A laboratory notebook entry that says the compound name and a milligram figure cannot be reconstructed later, because the formula weight it implied is not recoverable. One that names the salt and hydration state and the certificate it came from can be checked years afterward. That is not bureaucracy; it is the difference between a record and a recollection.
Questions this primer gets asked
A certificate reports a purity figure and calls the product NAD. What is missing?
Four fields, at minimum. Which species the figure describes, since the oxidized and reduced forms and the phosphorylated relative are different compounds that a bare name does not separate. The separation mode, because a conventional reversed-phase gradient barely retains this analyte and co-elution inflates the number. The detection wavelength, because an impurity invisible at one wavelength can be plain at another and the free base responds weakly near 260 nanometers. And the salt and hydration state, without which a weight cannot be converted into an amount of substance. A percentage with none of these alongside it is not comparable with any other percentage, including one from the same supplier on a different lot.
Does an exact mass measurement settle identity here the way it does for a peptide?
It does a different job. For a peptide, an observed mass is compared against a mass calculated from a stated sequence, so the measurement is effectively testing an ordering of subunits. There is no sequence here, so a high-resolution mass measurement fixes the elemental composition and rules out neighbors that differ in composition, which includes the phosphorylated relative and most hydrolysis fragments. What it does not do alone is establish connectivity or stereochemistry, which is why nuclear magnetic resonance earns its place on a small-molecule document. Phosphorus nuclear magnetic resonance in particular reports directly on the pyrophosphate bridge, and proton spectra report on the ring and anomeric environments. Mass plus nuclear magnetic resonance plus a reference standard comparison is the complete answer.
Why do two laboratories report different purity percentages for the same lot?
Usually method rather than material. Three variables dominate. Separation mode comes first: a poorly retaining method integrates related nucleotides into the main peak and returns a higher figure than a method that resolves them. Detection wavelength comes second: at 260 nanometers the response is dominated by adenine-containing species and the free base is under-represented, while at 340 nanometers only reduced material appears at all. Sample age and handling come third, because this material hydrolyzes in solution and a sample prepared some hours before analysis is not the sample that left the vial. Before treating a discrepancy as a quality dispute, compare those three fields; they close most of the gap.
What does comparison against a certified reference standard add?
It converts identity from a calculation into a measurement. For most research peptides no authentic standard exists, so a certificate can only compare an observed mass against a number computed from a claimed sequence, and the claim itself is never independently tested. This compound has been a commercial biochemical reagent for generations and authentic standards of established quality are obtainable, so a laboratory can run the standard and the lot under identical conditions and compare retention, spectral profile and mass directly. That comparison catches things a calculation cannot, including the phosphorylated relative, which shares a mass relationship that is easy to misread on a document but is unambiguous when the two are chromatographed side by side. A supplier who does not offer it is choosing not to.
Can a single buffer serve work with both the oxidized and the reduced form?
Not without accepting a loss. The oxidized form has an electron-poor pyridinium ring whose reactive carbon is open to attack by hydroxide, so it degrades increasingly quickly as pH rises above neutral. The reduced form no longer has a pyridinium ring but is instead susceptible to acid-catalyzed chemistry, so it degrades in mildly acidic solution and is comparatively stable in alkali. The preferences are genuinely opposite and there is no shared optimum, which is why the two are kept in separate conditions and why a shared stock buffer is a slow, silent source of error. The same opposition is useful when it is deliberate, since it is what allows the two pools to be extracted selectively from a single sample.
Where exactly is the boundary between the settled biochemistry and the weaker claims?
The boundary sits at the word add. Everything about how this coenzyme behaves inside enzyme active sites is settled: hydride transfer chemistry, the stereospecificity of that transfer, the stoichiometry of dehydrogenase reactions, the biosynthetic and salvage routes, the separate handling of the phosphorylated pool. Everything about what happens when the compound or a precursor is supplied to a system is a separate and much weaker literature, largely preclinical, heavily rodent-weighted, and dominated by studies whose endpoint is a metabolite concentration in an accessible compartment rather than a function. The second borrows credibility from the first because they share a name. A citation supporting a supplementation sentence with an enzymology reference is the characteristic tell.
Where to read next
- Peptide purity versus peptide identity for research labs the sequence-based workflow this compound does not fit
- How to review a peptide certificate of analysis field-by-field review, and which fields change for a small molecule
- Reading an HPLC chromatogram: purity by area how area percent is produced and where it misleads
- NAD+ 500 mg research material structure, redox chemistry and analytical notes for the listing
- Third-party lab testing and COAs
All materials described here are supplied strictly for laboratory research use. They are not drugs, foods, supplements, cosmetics or medical devices, and they are not for human or veterinary use, diagnostic use, or any form of consumption or intake. Nothing in this guide describes what any compound does in a person or animal, and nothing here is a recommendation to acquire, prepare or use any material outside a controlled research setting. Analytical descriptions are general explanations of common laboratory methods.